NEWS.. for those who sold yesterday.
ChromoCure, Inc. Announces Major Therapeutics Research "Project Boveri: Find the Cure" [KCVDMMF]
RENO, NV, Feb 02 (MARKET WIRE) --
ChromoCure, Inc. (PINKSHEETS: KKUR) announced today the launch of a major
new research initiative targeting Cancer Therapy and Cure. The Company
has realigned its business strategy due to corroboration by recent
Medical Research publications that both validated ChromoCure's
chromosomal/aneuploidy theory of cancer and immediately established the
company's proprietary ChromoSomal Scanner technology in the forefront of
both cancer detection and research. The company will announce new
partnerships, products, licensing, and laboratory activities based on
this research-oriented alignment.
Research has conclusively, and irrefutably demonstrated aneuploidy as a
more accurate predictor of cancer than cytological/histological analysis
or genetic marker-based diagnostics that are the only other methods in
existence today. ChromoCure's proprietary technology and understanding of
cancer also suggest non-toxic and non-invasive approaches to cancer
therapy and cure research.
The company's technology and research combined with unique insights
provided by the chromosomal theory of cancer paves the way for
non-invasive and non-toxic solutions to cancer therapeutics and disease
eradication. ChromoCure's ChromoSomal Scanner Technologies, encompassing
proprietary designs, processes, and algorithms, provides significant
advantage in delivering important and significant results in both therapy
and cure.
Support by these recent third party medical findings, the Company is
calling for a stepped up collaborative approach through its "Project
Boveri: Find the Cure" initiative; and is inviting industry, institutions,
medical research centers and government to partner in this initiative. The
company has already established a special section of its web site
dedicated to this project and research outreach. The Company's recently
announced diagnostic partnership program with pathologists and diagnostic
labs will be incorporated into Project Boveri in order to broaden
awareness of the company's technology.
The company will provide cancer detection and progression measurement
services using its own equipment to research partners participating in the
Project Boveri initiative. "Project Boveri" is named after Theodor Boveri
who first described the chromosomal/aneuploidy theory of cancer diagnosis
nearly a century ago.
The company will soon announce the details on various collaborative
research centers participating in "Project Boveri: Find the Cure".
About ChromoCure
ChromoCure develops and provides proprietary cancer detection systems and
technologies. The Company's proprietary ChromoCure CS200 Chromosomal
Scanner system has been proven accurate and efficient in the measurement
of the unique genomic characteristic found in 100% of all cancers and
never found in normal cells. The Company's detection technology has been
proven to have an effective accuracy of 100% for all cancers at all
stages. The Company believes its technology will become the worldwide
gold standard for cancer detection, progression measurement, and research
for both therapy and cure.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS (and are
incorporated herein by reference) and should be read before any investment
decision.
ChromoCure, Inc.
www.ChromoCure.com
info@chromocure.com
Tel 1.775.636.654
Copyright 2010, Market Wire, All rights reserved.
